Ok, So in my typical review of the CC, I thought it was good. Again, review what has been going on with the company over the last two years and what they have accomplished. Are we all rich beyond our dreams? Doing pretty good I would say for those who have been around for a while. They are doing things right. Very calculated. A lot going on in many fronts. The call was detailed and did not sound as if Gerald was trying to cover anything up that was not already discussed in the past. They continue to learn from past mistakes/blunders (which aren't many) and are on a path to make AMBS a world class company. Think of the amount of directions and opportunities that exist. If any one of them comes to fruition, we will be fine. Based on how careful they are being bringing Lympro to market, I would say we are in good hands. To those who are unhappy with the direction AMBS is going, I say, "please enlighten us". What are we missing? All the people that surround this company, the research that is being done on MANF independent of AMBS, a blood test that makes economical sense for major pharma, ELTZ for Parkinsons, etc etc etc. Just sayin! The PPS is going to do what its going to do, especially down here in OTC land. Stop looking every minute and realize and remember why you invested in the first place. Heck, when I got here all we had was MANF. That was enough for me at the time. Gerald is not here to mislead investors for his own greed as some might suggest on other boards, They have a vision and are working hard to make it a reality. I have to respect that. Thats what makes me a shareholder. 2.7 million strong for over two years and I still sleep fine. Nothing has changed from the last quarter or even last quarter last year in terms of execution. The fact that R&D expense increased is a positive. I would have been worried had it gone down. Then I would be wondering what they are doing with their time. Ok, so thats my two cents for the quarterly CC. Just thought I would share my thoughts. Peace!
Ok, So in my typical review of the CC, I thought it was
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Lundbeck's Board Leadership Transitions into New Era
A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...
Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action
Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....
Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note
AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...
Continue Reading
Faith and Resilience in China: The Legacy of the Long March
History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...
Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring
Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...
Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver
You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...
Continue Reading
UEG's New Advisory Board: Elevating Patient Voices
Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...
Continue ReadingTop 5 Most Recently Viewed Articles
Westgate Energy's Drilling Accomplishments and Financial Update
Overview of Recent Developments Westgate Energy Inc. (TSXV: WGT) has released its latest financial results along with updates on its three well drilling program. The Company is thrilled to share positive advancements since it has successfully filed its unaudited financial and operational outcomes covering a significant quarter in its operations. Financial Highlights The...
Continue Reading
Warren Buffett's Investment Strategy: A Guide for Investors
Insights into Buffett's Investment Philosophy Warren Buffett is a name that resonates with wise investing. Over the years, he’s built his reputation on a foundation of simplicity and strategic insight. While many contemporary investors chase after fleeting trends, Buffett sticks to the fundamentals, offering a timeless roadmap for achieving long-term success in the...
Continue Reading
TeleRare Health Introduces Virtual Genetic Consults for Patients
TeleRare Health Launches Virtual Genomic Consultation Service TeleRare Health has proudly announced the commencement of its Virtual Genomic Consults, providing immediate support for patients facing challenges with rare diseases and genetic conditions. This innovative initiative is particularly beneficial for those navigating the complex world of rare and genetic disorders...
Continue Reading
BrowserStack Unveils Major Employee Stock Ownership Program
BrowserStack Launches $125 Million ESOP and Share Buyback BrowserStack, a leader in software testing solutions, has made waves with their announcement of a substantial $125 million Employee Stock Ownership Plan (ESOP) and share buyback program. Benefiting over 500 current and former employees along with early investors, this initiative marks the company's third buyback,...
Continue Reading
Insight into Banijay Group's Weekly Share Activities
Banijay Group Share Transactions Overview Banijay Group N.V. is a name that resonates within the global entertainment industry, orchestrating an array of transactions that reveal its market dynamics. Recently, the company reported various share transactions conducted between June 23 and June 30. This disclosure aligns with the authorization granted during the recent...
Continue Reading